Zymeworks (ZYME) Profit After Tax (2021 - 2026)
Zymeworks (ZYME) posted Profit After Tax of -$486000.0 for Q1 2026, up 99.41% sequentially from -$82.0 million in Q4 2025, and up 97.8% YoY from -$245702.8 in Q1 2025.
Zymeworks (ZYME) Profit After Tax (2021 - 2026) Analysis & Trends
Zymeworks has reported Profit After Tax for 6 years, with the latest figure at -$486000.0 in Q1 2026.
- Quarterly Profit After Tax rose 97.8% year-over-year to -$486000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.1 million (up 29.14% YoY) and the FY2025 annual result came in at -$81.1 million, up 34.06% from the prior year.
- Profit After Tax climbed to -$486000.0 in Q1 2026 per ZYME's latest filing, from -$82.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at $309.4 million in Q4 2022 and troughed at -$123.6 million in Q4 2024.
- A 5-year average of -$12.1 million and a median of -$1.5 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 492.78% in 2024, then tumbled 1870.56% in 2025.
- Over 5 years, Profit After Tax stood at $309.4 million in 2022, then plunged by 137.82% to -$117.0 million in 2023, then decreased by 5.65% to -$123.6 million in 2024, then surged by 33.66% to -$82.0 million in 2025, then surged by 99.41% to -$486000.0 in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$486000.0, -$82.0 million, and -$19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -45.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.15 Mn |
| Mar 31, 2026 | -486,000.00 |
| Dec 31, 2025 | -82.03 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | -22.09 Mn |
| Dec 31, 2024 | -123.65 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -117.04 Mn |
| Sep 30, 2023 | -485,000.00 |
| Jun 30, 2023 | -1.87 Mn |
| Mar 31, 2023 | 720,000.00 |
| Dec 31, 2022 | 309.43 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | 172.69 Mn |
| Sep 30, 2021 | -60.58 Mn |